Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis

Abstract

To the Editor: Dupilumab, a monoclonal antibody that blocks T helper type 2 cytokines,1-4 is approved for the treatment of cutaneous manifestations of atopic dermatitis. Unfortunately, dupilumab use can result in ophthalmic complications. In the inaugural phase 3 clinical trials, 14% to 19% of patients reported dupilumab-associated conjunctivitis but were not examined by an ophthalmologist.1,4 Thus, it is possible that some of these patients could have experienced a more severe form of ocular surface disease than simple reactive conjunctivitis.